Efficacy and safety of enzyme-replacement-therapy with agalsidase alfa in 36 treatment-naïve Fabry disease patients
Abstract Background Fabry disease (FD) is an X-linked lysosomal storage disorder resulting from the α-galactosidase A gene mutations. Enzyme-replacement-therapy (ERT) products for FD currently used include agalsidase alfa and agalsidase beta. There are many reports on efficacy and safety of ERT. How...
保存先:
| 主要な著者: | , |
|---|---|
| フォーマット: | 図書 |
| 出版事項: |
BMC,
2017-06-01T00:00:00Z.
|
| 主題: | |
| オンライン･アクセス: | Connect to this object online. |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|
インターネット
Connect to this object online.3rd Floor Main Library
| 請求記号: |
A1234.567 |
|---|---|
| 所蔵 1 | 利用可 |